Synthes to fight off-label promotion charges
This article was originally published in Clinica
Swiss orthopaedics firm Synthes is to defend itself against a charge of allegedly promoting the use of its Norian XR calcium phosphate bone void filler for unapproved indications. The firm received an indictment from the US attorney for the Eastern district of Pennsylvania but claims that “marketing practices in connection with Norian XR were proper”. Norian XR was granted FDA approval in 2002 for the treatment of bone voids or defects in the skeletal system. According to Synthes, the technology was marketed from 2002 to 2004, when approximately 200 units were sold and revenue of $400,000 was generated.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals